To investigate the expression of serum FGF-23 (fibroblast growth factor-23,FGF-23) in patients with left ventricular hypertrophy on maintenance hemodialysis after treatment with Qiliqiangxin Capsule and its effect on cardiac function.
Forty-two patients with chronic kidney disease stage 5 who were on maintenance hemodialysis in our hospital's hemodialysis center from January 2017 to December 2018 were selected,and divided into two groups according to the random number method. The control group had 17 cases and the treatment group had 25 cases. Patients in the control group were given basic treatment.The treatment group was given Qiliqiangxin Capsule on the basis of basic treatment. By comparing with the control group,the improvement of cardiac function,the change of serum FGF-23,and the left ventricular mass index of patients after 12 weeks of treatment with Qiliqiangxin Capsule were analyzed,and the relevant data were analyzed statistically.
In patients in the treatment group,after 12 weeks of treatment with Qiliqiangxin Capsule,serum FGF-23 levels in CKD stage 5 patients with left ventricular hypertrophy decreased.The difference between the two groups was statistically significant (P< 0.05). the cardiac function of the treatment group was significantly improved,and the difference was significantly better than that of the control group. The difference was statistically significant(P< 0.05).
Qiliqiangxin Capsule can down-regulate the serum FGF-23 level in patients with CKD stage 5 left ventricular hypertrophy and improve their cardiac function.